Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV)

Area of Science:

• Inorganic Chemistry
• Pharmacology
• Endocrinology

Background:

• Vanadium compounds, including vanadyl and vanadate complexes, show potential for normalizing blood glucose levels in diabetic models.
• Developing effective anti-diabetic agents requires exploring various coordination modes (V-O, V-N, V-S) in vanadium complexes.

Purpose of the Study:

• To synthesize and evaluate a novel bis(picolinato)oxovanadium (IV) complex (VPA) for its insulin-mimetic properties.
• To assess the efficacy of VPA in normalizing blood glucose levels in streptozotocin (STZ)-induced diabetic rats.
• To determine the duration of action and oral activity of VPA as an anti-diabetic agent.

Main Methods:

• In vitro assessment of insulin-mimetic effects by measuring inhibition of free fatty acid release in isolated rat adipocytes stimulated with epinephrine.
• In vivo administration of VPA (intraperitoneally and orally) to STZ-induced diabetic rats.
• Monitoring of serum glucose levels and body weight changes in diabetic rats during and after VPA treatment.

Main Results:

• VPA demonstrated significant insulin-mimetic effects in vitro, comparable to insulin.
• Oral and intraperitoneal administration of VPA effectively normalized blood glucose levels in STZ-diabetic rats.
• Following 14 days of oral VPA administration, blood glucose levels remained normalized for approximately 30 days, accompanied by weight gain.

Conclusions:

• Bis(picolinato)oxovanadium (IV) (VPA) is an orally active vanadyl complex with potent, long-lasting insulin-mimetic properties.
• VPA shows promise as a therapeutic agent for managing insulin-dependent diabetes mellitus (IDDM) in preclinical models.
• The study highlights the potential of VPA for sustained glycemic control in diabetes treatment.